Jul 2013

celyad

Sole Global Coordinator & Joint Bookrunner

€ 26.4 million

Initial Public Offering

Cardio3

Cardio3 BioSciences is a Belgian biotechnology company aiming to heal heart failure

Cardio3 BioSciences floated on Euronext Brussels and Euronext Paris
Proceeds of the IPO were dedicated to fund European phase III trials of its flagship product, C-Cure
Kempen & Co acted as Sole Global Coordinator and Joint Bookrunner